Erudio Healtherudio.com
Sponsor
Daiichi Sankyo trials: what clinicians said in public
HCP commentary reports on 2 clinical trials sponsored by Daiichi Sankyo: IDeate-Lung01 and IDeate-Lung02. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 30 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Daiichi Sankyo; Daiichi Sankyo Co., Ltd.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| IDeate-Lung02 NCT06203210 · Daiichi Sankyo | relapsed small cell lung cancer | Phase 3 | 161 | 33 | Standard | Nov 5, 2026 | Preview |
| IDeate-Lung01Free NCT05280470 · Daiichi Sankyo | pretreated extensive-stage small cell lung cancer | Phase 2 | 274 | 73 | Standard | Nov 3, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| DESTINY-Breast04 NCT03734029 · Daiichi Sankyo DeepView → | HER2-low unresectable or metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast05 NCT04622319 · Daiichi Sankyo DeepView → | HER2-positive residual invasive breast cancer following neoadjuvant therapy | Phase 3 | Deep | View | |||
| DESTINY-Breast03 NCT03529110 · Daiichi Sankyo DeepView → | HER2-positive unresectable and/or metastatic breast cancer | Phase 3 | Deep | View | |||
| TROPION-Lung05 NCT04484142 · Daiichi Sankyo DeepView → | advanced or metastatic NSCLC with actionable genomic alterations | Phase 2 | Deep | View | |||
| DESTINY-Gastric04 NCT04704934 · Daiichi Sankyo DeepView → | HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma | Phase 3 | Deep | View | |||
| DESTINY-Lung02 NCT04644237 · Daiichi Sankyo DeepView → | HER2-mutant metastatic non-small-cell lung cancer | Phase 2 | Deep | View | |||
| DESTINY-Gastric01 NCT03329690 · Daiichi Sankyo Co., Ltd. DeepView → | HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Deep | View | |||
| DESTINY-Breast01 NCT03248492 · Daiichi Sankyo DeepView → | HER2-positive metastatic breast cancer previously treated with T-DM1 | Phase 2 | Deep | View | |||
| DESTINY-CRC01 NCT03384940 · Daiichi Sankyo Co., Ltd. DeepView → | HER2-expressing metastatic colorectal cancer | Phase 2 | Deep | View | |||
| HERTHENA-Lung02 NCT05338970 · Daiichi Sankyo DeepView → | advanced EGFR-mutated nonsquamous NSCLC after third-generation EGFR TKI | Phase 3 | Deep | View | |||
| HERTHENA-Lung01 NCT04619004 · Daiichi Sankyo DeepView → | previously treated locally advanced or metastatic EGFR-mutated NSCLC | Phase 2 | Deep | View | |||
| TROPION-Lung02 NCT04526691 · Daiichi Sankyo DeepView → | advanced or metastatic NSCLC | Phase 1 | Deep | View | |||
| TROPION-PanTumor01 NCT03401385 · Daiichi Sankyo Co., Ltd. DeepView → | advanced solid tumors | Phase 1 | Deep | View | |||
| DESTINY-Breast02 NCT03523585 · Daiichi Sankyo DeepView → | HER2-positive metastatic breast cancer previously treated with T-DM1 | Phase 3 | Deep | View | |||
| DESTINY-Gastric02 NCT04014075 · Daiichi Sankyo DeepView → | HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Deep | View | |||
| TROPION-Lung08 NCT05215340 · Daiichi Sankyo DeepView → | first-line PD-L1-high advanced or metastatic NSCLC | Phase 3 | Deep | View | |||
| TROPION-Lung07 NCT05555732 · Daiichi Sankyo DeepView → | PD-L1 TPS <50% advanced non-squamous non-small-cell lung cancer | Phase 3 | Deep | View | |||
| TROPION-Lung01 NCT04656652 · Daiichi Sankyo DeepView → | previously treated advanced or metastatic NSCLC | Phase 3 | Deep | View | |||
| REJOICE-Ovarian01 NCT06161025 · Daiichi Sankyo DeepView → | platinum-resistant high-grade ovarian, peritoneal or fallopian tube cancer | Phase 2/Phase 3 | Deep | View | |||
| QuANTUM-Wild NCT06578247 · Daiichi Sankyo StandardView → | newly diagnosed FLT3-ITD-negative acute myeloid leukemia | Phase 3 | Standard | View | |||
| REJOICE-PanTumor01 NCT06660654 · Daiichi Sankyo StandardView → | advanced or metastatic solid tumors | Phase 2 | Standard | View | |||
| DESTINY-Lung01 NCT03505710 · Daiichi Sankyo StandardView → | HER2-overexpressing or -mutated metastatic non-small cell lung cancer | Phase 2 | Standard | View | |||
| QuANTUM-First NCT02668653 · Daiichi Sankyo StandardView → | newly diagnosed FLT3-ITD-positive acute myeloid leukemia | Phase 3 | Standard | View | |||
| TROPION-Urothelial03 NCT07129993 · Daiichi Sankyo FocusedView → | advanced urothelial carcinoma after enfortumab vedotin plus pembrolizumab | Phase 2/Phase 3 | Focused | View | |||
| IDeate-PanTumor01 NCT04145622 · Daiichi Sankyo FocusedView → | advanced solid tumors | Phase 1/Phase 2 | Focused | View | |||
| DESTINY-CRC02 NCT04744831 · Daiichi Sankyo FocusedView → | HER2-positive advanced colorectal cancer | Phase 2 | Focused | View | |||
| NCT03260491 NCT03260491 · Daiichi Sankyo FocusedView → | Not given | Phase 1 | Focused | View | |||
| NCT04676477 NCT04676477 · Daiichi Sankyo FocusedView → | locally advanced or metastatic EGFR-mutated NSCLC | Phase 1 | Focused | View | |||
| IDeate-Lung03 NCT06362252 · Daiichi Sankyo FocusedView → | extensive-stage small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||
| IDeate-Esophageal01 NCT06644781 · Daiichi Sankyo FocusedView → | pretreated advanced or metastatic esophageal squamous cell carcinoma | Phase 3 | Focused | View | |||